49 min ago
Isis Pharmaceuticals Inc 1,800 Shares of Regulus Therapeutics Stock
Regulus Therapeutics Director Isis Pharmaceuticals Inc 1,800 shares of the company's stock in a transaction that occurred on Wednesday, July 9th.
Trending on the Topix Network
Wed Jul 02, 2014
Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For...
"Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline.
Contract Pharma Breaking News
Isis Earns GSK Milestone
Isis Pharmaceuticals, Inc. has earned a $1 million payment from GlaxoSmithKline for the advancement of its development program for antisense drugs to treat hepatitis B virus .
Thu Jun 26, 2014
Isis Receives $1M Milestone From GSK For FAP Drug
Isis Pharmaceuticals announced this week that it has earned a $1 million milestone payment from GlaxoSmithKline after advancing its investigational drug ISIS-TTR Rx in a Phase II/III study in patients with familial amyloid polyneuropathy .
Wed Jun 25, 2014
Insider Selling: ISIS Pharmaceuticals SVP Sells 11,200 Shares of Stock
ISIS Pharmaceuticals SVP C Frank Bennett sold 11,200 shares of the company's stock in a transaction dated Monday, June 23rd.
Tue Jun 24, 2014
Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For Advancing ISIS-TTR Rx
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
Mon Jun 23, 2014
The Motley Fool
Better Buy: Isis Pharmaceuticals vs. Arrowhead Research
Earlier this year, clinical-stage biotechs fell in dramatic fashion, as investors turned toward bigger health-care names generating revenue from approved products.
Thu Jun 19, 2014
ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart Attack Drug
Isis Pharmaceuticals gained more than four percent in pre-market trading after information related to its pipeline drug for lowering triglycerides landed on the New York Times' front page.
Wed Jun 18, 2014
Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx
ISIS-AR is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor .
Mon Jun 16, 2014
Applied Clinical Trials
Isis Pharmaceuticals Reports Final Phase 2 Data on Isis-GCGR RX...
Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing Treated patients achieved statistically significant reductions in measures of glucose control Isis to host an investor event and live webcast at 6:30 a.m. PDT on Monday, June 16 in San Francisco Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX ... (more)
Fri Jun 13, 2014
A Pax Romana May Be Bad For Markets
Increasing geopolitical conflict disrupts the vacuum that puts the current market at risk for unexpected moves in the absence of obvious catalysts.
Isis Pharmaceuticals Inc Files (8-K) Disclosing Submission of Matters to a Vote of Security Holders
Proposal 2: Ratification of the appointment of a director to hold office until the 2015 Annual Meeting: BROKER FOR WITHHELD ABSTAIN NON-VOTES Breaux Castleman 82,210,674 2,070,994 139,740 17,393,063 appointment by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the ... (more)
Thu Jun 12, 2014
ISIS Pharmaceuticals CEO Unloads $368,060 in Stock
ISIS Pharmaceuticals CEO Stanley T. Crooke sold 11,000 shares of the company's stock in a transaction dated Tuesday, June 10th.